What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist - a synthetic peptide that mimics the action of the naturally occurring hormone GLP-1 in the body. Originally developed for the treatment of type 2 diabetes, semaglutide gained widespread attention after clinical trials demonstrated remarkable efficacy for weight management. It is one of the most rigorously studied peptide therapies available, with extensive clinical trial data supporting its use.
The molecule appears under several brand names that are marketed for different indications, including weight management in adults with obesity or overweight with at least one weight-related comorbidity, and type 2 diabetes at different doses. The compounded form of semaglutide is also available through licensed compounding pharmacies under U.S.-licensed physician prescription. Compounded medications are not interchangeable with the brand-name medications they may reference.
Semaglutide represents a significant advancement in the treatment of obesity - a chronic metabolic disease that affects over 40% of American adults. Unlike previous weight loss medications that often produced modest results with significant side effects, semaglutide has demonstrated the ability to produce substantial, sustained weight loss when combined with lifestyle modifications.
How Semaglutide Works
Semaglutide works by binding to GLP-1 receptors throughout the body, triggering several complementary mechanisms that support weight management. In the brain, it acts on appetite regulation centers - particularly the hypothalamus - to reduce hunger and increase feelings of fullness (satiety). Patients often describe a fundamental shift in their relationship with food, reporting reduced cravings and the ability to feel satisfied with smaller portions.
In the gastrointestinal tract, semaglutide slows gastric emptying, meaning food stays in the stomach longer. This contributes to prolonged satiety after meals and reduced caloric intake. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon release, improving blood sugar regulation. These metabolic effects contribute to improved insulin sensitivity and reduced cardiovascular risk factors.
Semaglutide has been engineered with a fatty acid chain that allows it to bind to albumin in the blood, extending its half-life to approximately one week. This is what enables once-weekly dosing - a significant convenience factor compared to medications requiring daily administration. The sustained receptor activation provides consistent appetite suppression and metabolic benefits throughout the dosing interval.
Clinical Trial Results
Research note
Semaglutide has one of the most robust clinical evidence bases of any weight management therapy. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program included multiple large-scale, randomized, double-blind, placebo-controlled trials involving thousands of participants. The results have been published in top-tier medical journals including the New England Journal of Medicine.
In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved an average weight loss of approximately 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. Many participants achieved weight loss of 15-20% or more. The STEP 2 trial in patients with type 2 diabetes showed average weight loss of 9.6%. Across the STEP program, semaglutide consistently demonstrated significant improvements in waist circumference, blood pressure, lipid profiles, and glycemic markers.
Long-term data from the STEP 5 trial showed that weight loss was maintained over a 2-year treatment period, with participants sustaining an average loss of approximately 15.2% of body weight. These results represent a substantial improvement over historical pharmacological approaches to weight management and approach the outcomes previously achievable only through bariatric surgery.
Benefits Beyond Weight Loss
While weight management is the primary outcome that draws patients to semaglutide, the brand-name clinical literature has reported additional cardiometabolic findings: reductions in blood pressure, changes in cholesterol profiles, reduced inflammatory markers, and improved glycemic control. The SELECT cardiovascular outcomes trial studied the brand-name finished product in overweight and obese adults without diabetes and reported a reduction in major adverse cardiovascular events. The compounded preparation has not undergone equivalent finished-product testing, so the brand-name trial findings should be read as evidence about the molecule and mechanism, not as a guarantee of identical outcomes from a compounded preparation.
Patient-reported outcomes during treatment often include changes in energy, sleep quality, and self-reported well-being. These reports are subjective and individual; outcomes cannot be guaranteed.
Emerging research is exploring potential applications of GLP-1 receptor agonists across additional metabolic and non-metabolic indications. These applications are under investigation.
Side Effects and Considerations
Safety note
The most common side effects of semaglutide are gastrointestinal in nature. Nausea is reported by approximately 40-45% of patients in clinical trials, though it is typically mild to moderate and tends to improve after the first few weeks of treatment. Other GI side effects include diarrhea, constipation, vomiting, and abdominal discomfort. The gradual dose escalation protocol is specifically designed to minimize these effects.
Less common side effects include headache, fatigue, dizziness, and injection site reactions. Rare but serious potential risks include pancreatitis, gallbladder disease (including gallstones), and potential thyroid effects. In animal studies, semaglutide was associated with thyroid C-cell tumors, leading to a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Semaglutide is contraindicated in patients with a history of medullary thyroid carcinoma, MEN2 syndrome, known hypersensitivity to semaglutide, and during pregnancy. Patients with a history of pancreatitis, gallbladder disease, or severe gastrointestinal conditions should discuss risks with their physician. Your Pep Club physician will review your complete medical history to ensure semaglutide is safe for you.
Who Should Consider Semaglutide?
Semaglutide for weight management is appropriate for adults with a BMI of 30 or greater (obesity) or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. It is intended for use in conjunction with a reduced-calorie diet and increased physical activity - not as a standalone solution.
Ideal candidates are individuals who have attempted to lose weight through lifestyle modifications alone without achieving adequate results. Semaglutide is not intended for cosmetic weight loss in individuals at a healthy weight. It is a medical treatment for a chronic metabolic condition, and appropriate patient selection is essential for both safety and efficacy.
At The Pep Club, your physician will evaluate your BMI, medical history, current medications, and weight management goals during your consultation. If semaglutide is appropriate, you will receive a prescription, comprehensive dosing instructions, dietary guidance, and ongoing physician monitoring throughout your treatment.
Frequently asked
How much weight can I expect to lose with semaglutide?
Clinical trials showed average weight loss of approximately 15% of body weight over 68 weeks. Individual results vary significantly based on starting weight, adherence to lifestyle modifications, and other factors. Some patients lose more, some less. Your physician will help set realistic expectations based on your specific situation.
Is semaglutide the same as Ozempic or Wegovy?
Semaglutide is the active ingredient in both Ozempic (marketed for type 2 diabetes) and Wegovy (marketed for weight management). The two brand-name medications differ in dose and indication. Compounded semaglutide contains the same active molecule but is prepared by a licensed compounding pharmacy rather than the brand manufacturer; the compounded preparation is not interchangeable with these brand-name medications.
Will I gain the weight back if I stop semaglutide?
Research shows that weight regain is common after discontinuing semaglutide, similar to other chronic disease treatments. This is because obesity is a chronic metabolic condition, not a temporary problem. Your physician will work with you on a long-term plan that may include continued treatment, gradual dose reduction, or transition strategies.
Can I take semaglutide if I have type 2 diabetes?
Yes - semaglutide was originally developed for type 2 diabetes management. However, dosing and monitoring protocols may differ. Your physician will coordinate with your endocrinologist or primary care doctor to ensure safe integration with your existing diabetes management plan.